https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2): 41-44, 2024

RIJPP Publications

ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/3234144

The Role of Epigenetics in Disease Development

Katu Amina H.

School of Natural and Applied Sciences Kampala International Uganda

ABSTRACT

Epigenetics, the study of heritable changes in gene expression without alterations to the DNA sequence, plays a critical role in the development of various diseases. These epigenetic mechanisms, which include DNA methylation, histone modifications, and non-coding RNA-mediated gene silencing, regulate essential cellular processes such as differentiation, development, and tissue-specific gene expression. Environmental factors and lifestyle choices influence these epigenetic changes, often leading to disease by modifying transcriptional profiles. This paper discusses the role of epigenetics in the onset and progression of diseases like cancer and cardiovascular disorders, highlighting the potential of epigenetic biomarkers for early diagnosis and the promise of epigenetic therapies. Understanding the intricate relationship between epigenetics and disease mechanisms can open new avenues for personalized treatment strategies.

Keywords: Epigenetics, DNA methylation, histone modification, disease development, cancer, cardiovascular diseases

INTRODUCTION

The DNA formula makes the proteins that drive all physiological processes. Epigenetics controls how and when a gene is expressed, producing important biological and physiological outcomes. Epigenetic mechanisms dictate the differentiation and functioning of tissues during different stages of life. Therefore, the role of epigenetics can be explored at different levels of development and across tissues, starting at conception. Epigenetic modifications are involved in mediating the impact of environmental and lifestyle factors in disease development, and characterizing the interplay between epigenetics and genetic risk factors remains one of the top priorities for a large number of studies in the interdisciplinary field of biomedicine [1]. Epigenetics refers to heritable changes in gene expression that alter DNA structure, impacting transcriptional activity. These modifications are crucial for cellular processes like differentiation, development, and signaling. Epigenetic changes can be passed to daughter cells and successive generations. Epigenetics is fundamental for physiological processes, especially in embryonic development. It is distinct from Darwinian evolution and was coined by C.H. Waddington to explain genotype-to-phenotype changes during development [2].

DEFINITION AND BASIC CONCEPTS

Epigenetics refers to the study of hereditary traits or specific interphases of cell division that do not directly come from a change in the DNA sequence. This field is named epigenetics because the mechanism operates "on top" or "above" genetics. In general, the mechanism of epigenetic gene expression is regulated through the structure of chromatin or chromosomes. The chromatin structure, which is also called the modification pattern of the chromosomes, includes patterns of DNA methylation, histone modifications, and higher-order structures of chromatin [3]. From an epigenetics perspective, each cell's chromosome has two structures: one that is more active in gene expression and one that is less permissive. Changes in histone tail modification and DNA methylation patterns can alter chromatin structure, leading to gene repression. Epigenetic changes occur slowly due to internal and external factors, while DNA sequence changes happen quickly. Stressful events and exposure to toxic chemicals can cause epigenetic changes without altering the DNA sequence. The Dutch Hunger Winter study

revealed that exposure during pregnancy led to weight and health issues in offspring, potentially linked to hypomethylation of the Igf2 gene [4].

EPIGENETIC MECHANISMS

Gene expression must be tightly regulated. One key mechanism for this is epigenetics, involving DNA modifications and RNA molecules. Epigenetic mechanisms silence genes or activate them. DNA is the most well-known epigenetic code. Histones modify the structure of DNA, affecting transcription. Histone marks can be inherited and play a role in development. Some marks are reversible and involved in learning and memory [5].

EPIGENETICS AND DISEASE

Epigenetic processes regulate gene transcription and translation without altering the DNA coding sequence. Therefore, alterations in these mechanisms can result in an abnormal phenotype that can predispose individuals to disease. One way such alterations may be involved in disease is through their effects in a cell-specific and disease stage-specific manner on the molecular pathways regulating the cellular processes that lead to the pathological features of the disease. Examples of these pathways include the promotion of fibrosis in cardiovascular pathologies and the induction of apoptosis or hyperproliferation in cancer [6]. The role of epigenetic mechanisms in disease will be discussed regarding their influence on disease transcriptional and proteomic profiles. The following sections will discuss examples in the research that focuses on discussing a class of diseases and elaborate on how interconnected the epigenome is to the hallmark or mechanism of action seen in this class of diseases. Cross-interacting systems and the methylation of DNA result in changes to the regulation of transcription. In many cases, these measurements are also modified by environmental exposures, further highlighting that they may be useful to understand disease. A main question that will be presented after these examples is whether there is a consensus on utilizing epigenetic information for health outcomes. Do we know enough to pinpoint actionable steps? [7].

CANCER

Epigenetic deregulation is important in the development and progression of many common diseases. This includes some of the most prevalent chronic diseases such as cancer, type II diabetes, and neuropathologies, including several that are involved in this study, including cancers of many organs. This study mostly focuses on epigenetic dysfunction in tumorigenesis [8]. Cancer is caused by genetic and environmental factors, leading to altered cells that display cancer hallmarks. DNA methylation, histone modification, and epigenetic changes are associated with poor prognosis. Epigenetic modifications can impact cellular processes and affect cancer adaptability. Targeting epigenetic changes can lead to new therapeutic options. Changes in epigenetic profiles can guide treatment decisions. More research is needed in this field [9].

CARDIOVASCULAR DISEASES

The increasing death rates globally from cardiovascular diseases highlight the desperate need for research into the field of non-genetic factors that could be highly relevant and offer a target to prevent cardiovascular diseases. Multiple lifestyle factors such as diet and exercise have already proven to have different roles in influencing epigenetic changes in the heart. The interplay between genetic susceptibility and environment shows that at-risk individuals are poised for differential, and sometimes hyperactive, responses to environmental stressors. Moreover, cardiovascular diseases have a strong non-immune inflammatory component, and epigenetic changes are a crucial part of the regulatory mechanisms controlling the complex cellular events occurring with inflammation in the heart [10]. In the search for potential candidate blood-based epigenetic biomarkers that could serve as an early predictor for cardiovascular diseases or subsets of it such as hypertrophic cardiomyopathies or coronary artery disease, a recent study profiled the genome-wide DNA methylation in multiple forms of heart pathologies compared to healthy controls. They found a unique set of differentially methylated human genes to be associated with heart disease pathology. Essentially, these changes facilitate the expression or activity of proteins involved in pathological processes including the development of viral myocarditis in preclinical models. Consequently, this highlights the value of identifying epigenetic modifications as we learn more about each type and how we can identify and treat these diseases. While further functional studies will refine the activity of the identified metabolism-related epigenetic mechanisms in heart failure, these pathways could also be the target of therapeutic interventions. Inhibiting adipose tissue NAD-dependent SIRT-3 activity with epigenetic drugs is a promising treatment strategy for older adult heart failure with a preserved ejection fraction and high metabolic risk. Given the role that sirtuin deacetylases have in heart health, this may provide a clue for treating late-onset heart failure. Sirtuin activators have already been discussed for years as potential lifestyle or therapeutic interventions in heart failure with preserved

ejection fraction, but results have been mixed. Therefore, the identification of key genes and their epigenetic mechanisms as targets for interventions could bring new opportunities for treating these diseases. In the future, epigenetic data could also be used to guide patient treatments, as we know this can be influenced by genetic factors and better stratify or predict interindividual variability. The rapid growth and affordability of technologies and tests to examine epigenetic information from a blood sample suggest the potential for more personalized approaches for diagnosis, prognosis, and disease tests in clinical practice [11].

EPIGENETIC BIOMARKERS IN DISEASE DIAGNOSIS

The development of epigenetics has increased interest in epigenetic biomarkers for disease diagnosis. Epigenetic biomarkers can provide detailed information about an individual's history and potential future disease status. They may offer a more specific readout than mRNA expression-level measurements and can indicate environmental exposures. In cancer diagnosis, DNA methylation increases diagnostic accuracy, especially when examining the most recent methylation state of the genome. Site-specific methylation analysis can detect cancer in the absence of traditional markers. DNA methylation is also being studied for cardiovascular disease detection. Efforts are underway to explore the potential use of the epigenome for cancer screening. There is a growing interest in identifying and validating epigenetic markers for clinical use [12].

THERAPEUTIC IMPLICATIONS OF EPIGENETICS

The ability to manipulate epigenetic processes for new potential therapeutic strategies is the cutting edge of translational epigenetics. The concept of 'epigenetic therapy' is an area that has received much interest and is the subject of clinical trials and future scientific study. Several drugs are already commercially available, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, which, in addition to being used as cancer therapy, are under investigation for clinical use in other diseases. In another example, pomalidomide is an oral immunomodulatory drug that targets the E3 ligase cereblon and leads to antitumor effects against several hematological malignancies. This drug not only affects proliferation but seems to indirectly affect the injured microenvironment, recognizing this condition as a comorbidity of multiple myeloma in the elderly. Epigenetic strategies have been used to promote the suppression of the microenvironment or inflammation in chronic lymphocytic leukemia patients. Epigenetic management also decreases graft versus host rejection in resistant cases, chronic graft versus disease management, psoriatic arthritis, intestinal bowel disease, or other preclinical models. The development of this strategy offers opportunities for the treatment of chronic diseases such as chronic kidney disease and diabetes. Epigenetic-based interventions and tailored therapy strategies also raise considerations about the ethical, social, or even economic impact of such approaches. Epigenetic therapy will connect treatments with patients whose conditions are more readily treatable following stratification studies to understand the risks and benefits of care for a given population. This strategy will also provide a level of patient safety that takes advantage of mutations in certain targets that worsen the disease. In summary, epigenetic therapy is already proving its market potential with a total value expected to reach $3,145.8 million in 2026, demonstrating how promising this new therapeutic strategy may prove to be in the clinical setting [13].

CONCLUSION

Epigenetics offers profound insights into disease mechanisms by bridging the gap between genetic predispositions and environmental influences. The involvement of epigenetic modifications in diseases like cancer and cardiovascular conditions underscores the significance of studying these mechanisms for early diagnosis and therapeutic interventions. Advances in epigenetic research have led to the discovery of biomarkers that can enhance disease prediction and guide personalized treatment strategies. Moreover, epigenetic therapies are emerging as promising tools to address diseases at the molecular level, offering a new frontier in precision medicine. As our understanding of epigenetics grows, so does the potential for revolutionizing disease diagnosis, prognosis, and treatment.

REFERENCES

1. Ramos-Lopez O, Milagro FI, Riezu-Boj JI, Martinez JA. Epigenetic signatures underlying inflammation: An interplay of nutrition, physical activity, metabolic diseases, and environmental factors for personalized nutrition. Inflammation Research. 2021 Jan;70:29-49. springer.com
2. Burton NO, Greer EL. Multigenerational epigenetic inheritance: Transmitting information across generations. InSeminars in cell & developmental biology 2022 Jul 1 (Vol. 127, pp. 121-132). Academic Press.

3. Rey O, Eizaguirre C, Angers B, Baltazar-Soares M, Sagonas K, Prunier JG, Blanchet S. Linking epigenetics and biological conservation: towards a conservation epigenetics perspective. Functional Ecology. 2020 Feb;34(2):414-27. wiley.com
4. Raj K, Horvath S. Current perspectives on the cellular and molecular features of epigenetic ageing. Experimental Biology and Medicine. 2020 Nov;245(17):1532-42.
5. Retis-Resendiz AM, González-García IN, León-Juárez M, Camacho-Arroyo I, Cerbón M, Vázquez-Martínez ER. The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium. Clinical Epigenetics. 2021 Dec;13(1):116. springer.com
6. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nature reviews Molecular cell biology. 2021 Feb;22(2):96-118. nature.com
7. Mahony C, O'Ryan C. Convergent canonical pathways in autism spectrum disorder from proteomic, transcriptomic and DNA methylation data. International journal of molecular sciences. 2021 Oct 5;22(19):10757.
8. Czarny P, Białek K, Ziółkowska S, Strycharz J, Barszczewska G, Sliwinski T. The importance of epigenetics in diagnostics and treatment of major depressive disorder. Journal of personalized medicine. 2021 Mar 1;11(3):167. mdpi.com
9. Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, Zengin G, Kamal MA, Gallo M, Montesano D, El Omari N. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: Mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022 Feb 25;12(3):367. mdpi.com
1. 10Jurdziński KT, Potempa J, Grabiec AM. Epigenetic regulation of inflammation in periodontitis: cellular mechanisms and therapeutic potential. Clinical epigenetics. 2020 Dec;12(1):186.
10. Yuan X, Huang J, Wen L, Novakovic B, Kilby MD, Tong C, Qi H, Saffery R, Baker PN. Genome-wide DNA methylation analysis of discordant monozygotic twins reveals consistent sites of differential methylation associated with congenital heart disease. Genomics. 2023 Mar 1;115(2):110565. sciencedirect.com
11. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine. Clinical epigenetics. 2022 Dec;14(1):44.
12. Angulo JC, Manini C, López JI, Pueyo A, Colás B, Ropero S. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments. Cancers. 2021 Apr 25;13(9):2071.

CITE AS: Katu Amina H. (2024). The Role of Epigenetics in Disease Development. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2):41-44. https://doi.org/10.59298/RIJPP/2024/3234144